Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases.
Several clinical and histopathologic features of 65 CD30+ cutaneous lymphoproliferations were evaluated for their diagnostic value between CD30+ primary versus secondary cutaneous lymphomas and for their prognostic significance. Primary cutaneous disease, spontaneous regression, and absence of extracutaneous spreading (but not age < or =60 years) were associated with a better prognosis. Epithelial membrane antigen, BNH9, CD15 or CBF.78 antigen were expressed in all types of cutaneous lymphoproliferations. However, epithelial membrane antigen immunoreactivity was more frequently expressed in CD30+ secondary cutaneous large-cell lymphoma. Among CD30+ primary cutaneous large-cell lymphoma, CD15 expression was only seen in localized skin lesions. P53 expression was not associated with spontaneous regression, extracutaneous spreading, or survival. Nested reverse transcriptase-polymerase chain reaction allowed the detection of NPM-ALK transcripts in 10 of 26 CD30+ primary and in 3 of 11 secondary cutaneous large-cell lymphomas. The ALK protein was detected in only 1 of 50 primary and in 4 of 15 secondary cutaneous CD30+ lymphoproliferations. In CD30+ primary cutaneous lymphoproliferation, NPM-ALK transcripts might be expressed by very rare normal or tumoral cells that are undetectable by immunohistochemistry. However, the expression of either NPM-ALK transcripts or ALK-protein was not correlated with prognosis or age in CD30+ cutaneous lymphoproliferations.
Vergier
B
B
Department of Pathology, CHU of Bordeaux and University of Bordeaux II, France.
Beylot-Barry
M
M
Pulford
K
K
Michel
P
P
Bosq
J
J
de Muret
A
A
Beylot
C
C
Delaunay
M M
MM
Avril
M F
MF
Dalac
S
S
Bodemer
C
C
Joly
P
P
Groppi
A
A
de Mascarel
A
A
Bagot
M
M
Mason
D Y
DY
Wechsler
J
J
Merlio
J P
JP
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm / Q000032:analysis; D003937:Diagnosis, Differential; D003955:Diagnostic Tests, Routine; D005069:Evaluation Studies as Topic; D005260:Female; D005602:France; D006801:Humans; D017730:Ki-1 Antigen / Q000276:immunology / Q000378:metabolism*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D016410:Lymphoma, T-Cell, Cutaneous / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008232:Lymphoproliferative Disorders / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D018396:Mucin-1 / Q000378:metabolism; D015514:Oncogene Proteins, Fusion / Q000378:metabolism; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012871:Skin Diseases / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D017730:Ki-1 Antigen; D018396:Mucin-1; D015514:Oncogene Proteins, Fusion; D016159:Tumor Suppressor Protein p53; C107023:p80(NPM-ALK) protein; D011505:Protein-Tyrosine Kinases